Mark E. Fraley

1.9k citations

32 papers · 1.0k indexed · h-index 19

Organic Chemistry top 5%
Toxicology top 5%
- Bioactive Compounds and Antitumor Agents 2
Molecular Biology
- DNA Repair Mechanisms 3
- Angiogenesis and VEGF in Cancer 3
Cell Biology
- Microtubule and mitosis dynamics 5
Oncology
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 6
- Cancer-related Molecular Pathways 3
Psychiatry and Mental health
- Migraine and Headache Studies 3

Co-authors: Andrew G. Myers Norma J. Tom Scott B. Cohen David J. Madar George D. Hartman Robert S. Rubino Kathleen Coll Kenneth A. Thomas
Cited by: Organic Chemistry Toxicology Molecular Biology
Journals: Bioorganic & Medicinal Chemistry Letters (10 papers)Journal of the American Chemical Society (3 papers)Expert Opinion on Therapeutic Patents (2 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Mark E. Fraley

32 papers receiving 960 citations

Peers

Countries citing papers authored by Mark E. Fraley

Since Specialization

Citations

This map shows the geographic impact of Mark E. Fraley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Fraley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Fraley more than expected).

Fields of papers citing papers by Mark E. Fraley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Fraley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Fraley. The network helps show where Mark E. Fraley may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark E. Fraley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark E. Fraley Line = papers co-authored together Mark E. Fraley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy Neurobiology of Disease ·P. Prajosh,Sarah Jinn,Lihang Yao,Aram Ahmad Muhamad,Monika Kandebo,Dawn Toolan,Nathan G. Hatcher,Lei Ma,Wei Lemaire,Gregory C. Adam,Christine Burlein,Yun Young Jeong,许威汉,Marla L. Watt,Eva-Maria Herring,Mark E. Fraley,Robert E. Drolet,Jacob Marcus,Sean M. Smith	2021	14
2	Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor Journal of Pharmacology and Experimental Therapeutics ·Eric L. Moore,Mark E. Fraley,Ian M. Bell,Christopher S. Burgey,Rebecca B. White,Chi‐Chung Li,Christopher P. Regan,Andrew Danziger,Maria S. Michener,Eric D. Hostetler,Pradeep Banerjee,Christopher Salvatore	2020	51
3	Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor (P4.10-021) Neurology ·Eric L. Moore,Christopher S. Burgey,Mark E. Fraley,Andrew Danziger,Christopher P. Regan,Chi‐Chung Li,Rebecca B. White,Pradeep Banerjee,Christopher Salvatore	2019	2
4	Adenosine analogue inhibitors of S-adenosylhomocysteine hydrolase Bioorganic & Medicinal Chemistry Letters ·Antonella Converso,Альберт Садовничий,Mark E. Fraley,R. M. Garbaccio,George D. Hartman,Gabriel Feitosa de Melo,John Majercak,Alexander McCampbell,Ryoji Fujizuka,William J. Ray,Mary J. Savage,Lars-Olof Nyhlén,Suzie Yeh,Στέλλα Τάκα,Rebecca B. White,Rena Zhang	2014	12
5	Pyridyl aminothiazoles as potent Chk1 inhibitors: Optimization of cellular activity Bioorganic & Medicinal Chemistry Letters ·Vadim Dudkin,Cheng Wang,Kenneth L. Arrington,Mark E. Fraley,George D. Hartman,Steven M. Stirdivant,Robert Drakas,Keith Rickert,Eileen S. Walsh,Kelly Hamilton,Carolyn A. Buser,James C.H. Hardwick,Weikang Tao,Stephen C. Beck,Xianzhi Mao,Robert B. Lobell,Laura Sepp‐Lorenzino	2012	6
6	Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates Bioorganic & Medicinal Chemistry Letters ·Vadim Dudkin,Keith Rickert,Constantine Kreatsoulas,Savina J. W. Lin,Kenneth L. Arrington,Mark E. Fraley,George D. Hartman,Maurice Bedot,Mari Ikuta,Steven M. Stirdivant,Robert Drakas,Eileen S. Walsh,Kelly Hamilton,Carolyn A. Buser,Robert B. Lobell,Laura Sepp‐Lorenzino	2012	20
7	3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts Bioorganic & Medicinal Chemistry Letters ·Edward J. Brnardic,Mark E. Fraley,R. M. Garbaccio,M. E. Layton,John M. Sanders,Chris Culberson,Marlene A. Jacobson,Brian C. Magliaro,Pete H. Hutson,Julie A. O’Brien,Sarah L. Huszar,Jason M. Uslaner,Kerry L. Fillgrove,Cuyue Tang,Yuhsin Kuo,Ching Ying Lee,George D. Hartman	2010	30
8	Stereospecific reduction of a potent kinesin spindle protein (KSP) inhibitor in human tissues Biochemical Pharmacology ·Chunze Li,Bing Lu,R. M. Garbaccio,杨金娥,Mark E. Fraley,George D. Hartman,Jingjing Ye,S. J. Firchow,Thomayant Prueksaritanont	2010	3
9	Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor ACS Medicinal Chemistry Letters ·R. M. Garbaccio,Edward J. Brnardic,Mark E. Fraley,George D. Hartman,Pete H. Hutson,Julie A. O’Brien,Brian C. Magliaro,Jason M. Uslaner,Sarah L. Huszar,Kerry L. Fillgrove,James H. Small,Cuyue Tang,Yuhsin Kuo,Marlene A. Jacobson	2010	14
10	Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia Expert Opinion on Therapeutic Patents ·Mark E. Fraley	2009	28
11	Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein Bioorganic & Medicinal Chemistry Letters ·Christopher D. Cox,Michael J. Breslin,David B. Whitman,Paul J. Coleman,R. M. Garbaccio,Mark E. Fraley,Matthew M. Zrada,Carolyn A. Buser,Eileen S. Walsh,Kelly Hamilton,Robert B. Lobell,Weikang Tao,Marc Abrams,Vicki J. South,Hans E. Huber,Nancy E. Kohl,George D. Hartman	2007	39
12	Discovery of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP Cancer Research ·Mark E. Fraley,L. Drumm Myers,Hans Joachim Kreutzer,Li-Na Teng,George D. Hartman,Clécia do Nascimento Cavalcante,Carolyn A. Buser,Weikang Tao,Hans E. Huber,Nancy E. Kohl	2005	1
13	Property-Based Design of KDR Kinase Inhibitors Current Medicinal Chemistry ·Mark E. Fraley,William F. Hoffman,Kenneth L. Arrington,Randy W. Hungate,George D. Hartman,Rosemary C. McFall,Kathleen Coll,Keith Rickert,Kenneth A. Thomas,Georgia B. McGaughey	2004	24
14	Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR Bioorganic & Medicinal Chemistry Letters ·Zhicai Wu,Mark E. Fraley,Mark T. Bilodeau,E. Tönges,杨金娥,Fatou Niasse Dia,George D. Hartman,Kathleen Coll,Keith Rickert,Jennifer M. Shipman,Bin Shi,Laura Sepp‐Lorenzino,Kenneth A. Thomas	2004	36
15	Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley,Kenneth L. Arrington,Carolyn A. Buser,Yard.Doç.Dr.Oya Beklan ÇETİN,Kathleen Coll,Christine Fernandes,George D. Hartman,William F. Hoffman,Joseph J. Lynch,Rosemary C. McFall,Keith Rickert,Romi Singh,Sheri Smith,Kenneth A. Thomas,Bradley K. Wong	2003	43
16	Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents Expert Opinion on Investigational Drugs ·George D. Hartman,Mark E. Fraley,Mark T. Bilodeau	2002	39
17	Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley,William F. Hoffman,Robert S. Rubino,Randall W. Hungate,Andrew J. Tebben,Ruth Z. Rutledge,Rosemary C. McFall,William R. Huckle,Richard Kendall,Kathleen Coll,Kenneth A. Thomas	2002	105
18	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley,Robert S. Rubino,William F. Hoffman,Змитриченко Юлия Геннадьевна,Kenneth L. Arrington,Randall W. Hungate,Mark T. Bilodeau,Andrew J. Tebben,Ruth Z. Rutledge,Richard Kendall,Rosemary C. McFall,William R. Huckle,Kathleen Coll,Kenneth A. Thomas	2002	79
19	Rapid X-ray diffraction analysis of HIV-1 protease–inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme Acta Crystallographica Section D Biological Crystallography ·Arianna Brambila,Ruijun Guo,Yihong Li,David B. Olsen,Mark E. Fraley,Randall W. Hungate,Lawrence C. Kuo	1998	27
20	Synthesis of (+)-dynemicin A and analogs of wide structural variability: establishment of the absolute configuration of natural dynemicin A Chemistry & Biology ·Andrew G. Myers,Mark E. Fraley,Norma J. Tom,Scott B. Cohen,David J. Madar	1995	70

About Mark E. Fraley

Mark E. Fraley is a scholar working on Structural Biology, Toxicology and Oncology, having authored 32 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (6 papers), Microtubule and mitosis dynamics (5 papers), DNA Repair Mechanisms (3 papers), Angiogenesis and VEGF in Cancer (3 papers), Cancer-related Molecular Pathways (3 papers), Migraine and Headache Studies (3 papers) and Bioactive Compounds and Antitumor Agents (2 papers). The work is most often cited by research in Organic Chemistry (587 citations), Toxicology (49 citations) and Molecular Biology (425 citations). Mark E. Fraley has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Andrew G. Myers, Norma J. Tom, Scott B. Cohen, David J. Madar, George D. Hartman, Robert S. Rubino, Kathleen Coll, Kenneth A. Thomas, William F. Hoffman and Mark T. Bilodeau. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of the American Chemical Society, Expert Opinion on Therapeutic Patents, Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact